| CAS ID: | 1037210-93-7 |
| Molecular Formula: | C29H48N2O3S |
| Molecular Weight: | 504.8 g/mol |
| Monoisotopic Mass: | 504.3386 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | SARIDEGIB | PATIDEGIB | IPI-926 | SARIDEGIB HYDROCHLORIDE | PATIDEGIB HYDROCHLORIDE |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C29H48N2O3S/c1-17-12-26-27(30-16-17)19(3)29(34-26)11-9-22-23-7-6-20-13-21(31-35(5,32)33)8-10-28(20,4)25(23)14-24(22)18(2)15-29/h17,19-23,25-27,30-31H,6-16H2,1-5H3/t17-,19+,20+,21+,22-,23-,25-,26+,27-,28-,29-/m0/s1 | See All |
| InChI Key: | HZLFFNCLTRVYJG-WWGOJCOQSA-N | |
| Smiles: | C[C@@H]1CN[C@@H]2[C@@H](C1)O[C@]3(CC[C@H]4[C@@H]5CC[C@@H]6C[C@@H](CC[C@]6(C)[C@H]5CC4=C(C)C3)NS(=O)(=O)C)[C@@H]2C | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT01371617 | Disease | Bone marrow fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | June 13, 2011 | Last Verified | November 15, 2012 |
| Sponsor | Infinity Pharmaceuticals, Inc. | ||
| PubChem: | 25027363 |
| ChEMBL: | CHEMBL538867 |